James S. Hu, MD

Clinical Associate Professor of Medicine (Clinician Educator)

Image of James S. Hu, MD
Is this your profile? Click to edit

Overview

James Hu, MD, FACP, is the medical director of the Sarcoma Program of USC, and is considered one of the nation’s experts in the disease. Dr. Hu has more than 20 years of clinical experience in medical oncology and brings this acumen to the bedside. Understanding the rarity of sarcoma cancers, Dr. Hu has the breadth of clinical experience as well as the academic discipline to provide each patient with an individualized treatment program. He has collaborated with other national experts to bring clinical trials to USC. He is a member of the Connective Tissue Oncology Society, and has linked the Sarcoma Program of USC with the international collaborative group: Sarcoma Alliance for Research through Collaboration (SARC), to further direct research into sarcoma.

Dr Hu has authored several review articles on sarcoma, in both national and international peer reviewed journals. As a former military commander of a combat support hospital, Dr. Hu has years of experience in the issues surrounding young adult disease and along with Dr. Siegel, is the co-director of the Adolescent and Young Adult program of USC and Children’s Hospital Los Angeles. This program offers specialized services tailored to adolescent and young adult patients who comprise a significant portion of patients diagnosed with sarcomas. Dr Hu and his medical oncology team pride themselves on patient accessibility and are committed to providing comprehensive oncology care to the patient with sarcoma.

Dr. Hu is a local Angeleno, having grown up in the neighborhood surrounding LAC+USC Medical Center. Dr Hu is proud to be a part of USC and grateful for an opportunity to give back to his community.

Awards

  • Meritorious Service Medal, 2013
  • Keck School of Medicine: Oncology Fellowship Teacher of the Year, 2011
  • American College of Physicians: Fellow, 2006

Publications

  • Atezolizumab for Advanced Alveolar Soft Part Sarcoma N Engl J Med. 2023 Sep 07; 389(10):911-921. . View in PubMed
  • Physician Burnout-Evidence That Leadership Behaviors Make a Difference: A Cross-Sectional Survey of an Academic Medical Center Mil Med. 2022 Oct 19. . View in PubMed
  • Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature J Med Case Rep. 2022 Jun 28; 16(1):252. . View in PubMed
  • Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma Mol Cancer Ther. 2021 01; 20(1):132-141. . View in PubMed
  • Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Cancer. 2021 03 01; 127(5):729-738. . View in PubMed
  • Predictors of readmission after craniotomy for meningioma resection: a nationwide readmission database analysis Acta Neurochir (Wien). 2020 11; 162(11):2637-2646. . View in PubMed
  • Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization? Chin Clin Oncol. 2019 Oct; 8(S1):S12.. View in PubMed
  • Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma JAAD Case Rep. 2018 Nov; 4(10):1004-1006. . View in PubMed
  • Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer Cancer. 2017 Dec 01; 123(23):4566-4573. . View in PubMed
  • Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. . View in PubMed
  • Contemporary Management of Retroperitoneal Soft Tissue Sarcomas Curr Oncol Rep. 2015 Aug; 17(8):39. . View in PubMed
  • Contrast-Enhanced Sonography for Monitoring Neoadjuvant Chemotherapy in Soft Tissue Sarcomas J Ultrasound Med. 2015 Aug; 34(8):1489-99. . View in PubMed
  • Salvage chemotherapy for refractory germ cell tumors Oncology (Williston Park). 2014 Jun; 28(6):498-500. . View in PubMed